Clinuvel Pharmaceuticals Limited · ASX:CUV
Clinuvel Pharmaceuticals — Investor Presentation (August 2025)
11 slides from Clinuvel Pharmaceuticals's investor presentation, Aug 28, 2025
Slide 1: Strategy Towards Diversification
STRATEGY TOWARDS DIVERSIFICATION Financial Year Ended 30 June 2025 INVESTOR BRIEFINGS : 28 August – 5 September 2025 PETER VAUGHAN Chief Financial Officer | MALCOLM BULL Head of Australia Operations & Investor Relations ASX: CUV | Börse Frankfurt: UR9 | ADR Level I: CLVLY
Slide 2: Forward-Looking Statement
FORWARD - LOOKING STATEMENT CLINUVEL GROUP This release contains forward - looking statements, which reflect the current beliefs and either Australia, the U. S., Europe, the UK, Israel, China, Japan, and/or LATAM regions of our expectations of CLINUVEL’s management . All statements other than statem
Slide 3: FY2025 Strong, consistent financial performance
FY2025 Strong, consistent financial performance Increase in revenues, cash, NPAT CONSOLIDATED ENTITY 30 June 2025 Change • global growth • controlled expenses Total Revenues, Interest and Other Income A$m 105.3 + 10% • Reinvested in R&D for future revenues Total Expenses A$m 53.7 + 20% 9th consecuti
Slide 4: Analyses of Expenses
ANALYSES OF EXPENSES Increase OPEX FY2025 [as planned] +20% KEY EXPENSES CATEGORIES ( A$m) • integrational efficiencies implemented in key operational functions Personnel-related • clinical & non - clinical development ramping up as forecast Materials and related expenses • materials and related exp
Slide 5: Long-Term Profitability
LONG - TERM PROFITABILITY ® Revenue growth, profitability from SCENESSE in EPP JUNE YEAR ( A$m) 9 years of growth in revenues CAGR 35% 120 55 90 45 controlled increase of expenses CAGR 20% 60 35 30 net profit margin 34% 25 0 reinvestment RD&I ~40% 15 -30 -60 5 2017 2018 2019 2020 2021 2022 2023 2024
Slide 6: Budgetary Planning
BUDGETARY PLANNING FY2021 - 25 expenses within budget FIVE - YEAR EXPENSES TO 30 JUNE 2025 ( A$m) CONTROLLED EXPENSES SUPPORT GROWTH 60 FY2021 - 25 expended* A$171.2m 50 40 Total of 5 - years projected in 2021* A$175.0m 30 20 3 - year budget to be released: 2H 2025 10 0 Maximum targeted annual FY202
Slide 7: Strongest Balance Sheet
STRONGEST BALANCE SHEET On 30 June 2024 2025 ASSETS & LIABILITIES ( A$m) 280 TOTAL ASSETS $231.1m $271.8m +18% 240 200 160 TOTAL LIABILITIES 120 • trade creditors $28.1m $30.9m +10% 80 • debt - free (20 th year) 40 0 Assets Liabilities CASH RESERVES $183.9m $224.1m +22% FY2021 FY2022 FY2023 FY2024
Slide 8: Focused Clinical Pipeline
FOCUSED CLINICAL PIPELINE EXPERTISE IN MELANOCORTIN PEPTIDES EARLY Ph II Ph III APPROVED ® SCENESSE in adult EPP ® SCENESSE in adolescent EPP ® SCENESSE in vitiligo ® SCENESSE in variegate porphyria ® NEURACTHEL (ACTH) - generic Cash Reserves equals Cash & cash equivalents plus Cash held in term dep
Slide 9: Catalysts and Calendar
CATALYSTS AND CALENDAR 2025 – 2026 EMA decision dosage expansion adults Q4 2025 COMMERCIAL ® GROWTH EMA re - file adolescents SCENESSE Q4 2025 ® SCENESSE ® Health Canada decision marketing authorisation: SCENESSE in EPP Q4 2025 Distribution expansion to 120 Specialty Centers USA – CA Q4 2025 ® NEURA
Slide 10: Analysts' Questions
Q & A ANALYSTS’ QUESTIONS
Slide 11: We appreciate your long-term support
We appreciate your long - term support Financial Year Ended 30 June 2025 INVESTOR BRIEFINGS : 28 August – 5 September 2025 PETER VAUGHAN Chief Financial Officer | MALCOLM BULL Head of Australia Operations & Investor Relations ASX: CUV | Börse Frankfurt: UR9 | ADR Level I: CLVLY
Clinuvel Pharmaceuticals — Investor Presentation (August 2025) on 6ix